查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1943550

寻常疣治疗市场－全球产业规模、份额、趋势、机会及预测（依产品、通路、地区及竞争格局划分，2021-2031年）

Prurigo Nodularis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球结节性痒疹治疗市场预计将从 2025 年的 9.7566 亿美元成长到 2031 年的 11.6907 亿美元，复合年增长率为 3.06%。

针对这种慢性神经免疫疾病的治疗策略包括药物疗法，例如局部皮质类固醇、全身性神经调节剂和生物目标，所有这些疗法都旨在缓解令人痛苦的搔痒和角化过度病变。该市场的成长主要得益于近期核准的新型单株抗体，这些特异性靶向搔痒通路，与传统的仿单标示外用药相比，疗效更佳。此外，临床上对诊断潜在的第二型发炎合併症的日益重视，也进一步扩大了适合接受全身性治疗的患者族群。

市场概览
预测期 2027-2031
市场规模：2025年 9.7566亿美元
市场规模：2031年 1,169,070,000 美元
复合年增长率：2026-2031年 3.06%
成长最快的细分市场 皮质类固醇
最大的市场 北美洲

然而，这些先进疗法的高昂采集费用构成了一项重大挑战，并可能限制其在医疗资金有限或报销政策严格的地区的市场渗透。长期坚持用药以维持疗效并预防症状復发，进一步加剧了这项经济负担。例如，2024年，欧洲皮肤病与性病学会报告称，临床试验数据显示，先前对尼莫利珠单抗治疗有效的患者中，停药后復发率高达75%，这凸显了持续疾病管理对于维持市场价值至关重要。

市场驱动因素

新型生物製药的商业化正在从根本上改变全球结节性痒疹治疗市场，引入核准的标靶治疗来取代疗效欠佳的仿单标示外用药。新核准的单株抗体在阻断搔痒-抓痒循环方面展现出优于传统免疫抑制剂的卓越能力，随着这一转变，其应用率也大幅提升，近期真实世界研究证实了治疗效果的持久性。根据赛诺菲在2024年9月欧洲皮肤病学会（EADV）上发表的度普利尤单抗中期分析，50.0%的接受治疗患者在6个月时搔痒强度显着降低。如此高的疗效对于应对疾病带来的巨大负担至关重要。根据高德美在2024年8月发布的新闻稿，光在美国就有多达18.1万人受结节性痒疹影响，这为这些已上市的生物製剂创造了庞大的潜在市场。

同时，强大的临床研发管线和研发投入正在加速市场扩张。这主要得益于兼具高效性和便捷给药方式的新一代口服小分子药物的研发竞赛。製药公司正大力投资JAK抑制剂和其他新型给药途径，以满足对注射生物製药抗药性或偏好口服给药的患者的需求。后期临床试验结果显示出改善长期症状控制的良好迹象。 Incyte公司在2024年9月举行的欧洲抗病毒药物研发协会（EADV）年会上公布的数据显示，最初对口服45毫克povoltinib有反应的患者中，89%的患者在第40週仍保持疗效。这些积极数据支持继续资金筹措和进行研发，以确保创新疗法的稳定供应，从而在未来十年内维持市场价值和竞争力。

市场挑战

新型药物疗法，尤其是生物目标，其高昂的购买成本是全球结节性痒疹治疗市场成长的一大障碍。儘管这些先进治疗方法能够改善临床疗效，但其高昂的价格却严重阻碍了市场渗透，尤其是在医保报销机制严格、公共医疗资金有限的地区。此外，疾病的慢性病程进一步加剧了这种经济压力，患者需要长期接受昂贵的治疗方法以防止症状復发，这不仅加重了支付方的预算负担，也增加了患者的自付费用。

因此，支付方通常会实施限制性准入通讯协定，从而延缓昂贵治疗方法的引入。这种疾病带来的巨大经济负担对市场可近性产生了负面影响。根据2024年国际药物经济学与结果研究学会（ISPOR）的数据，真实世界临床数据显示，结节性痒疹患者的医疗保健费用显着高于对照组，每位患者的费用差异高达5736美元。这种日益增长的经济负担限制了先进治疗方法的应用，最终阻碍了市场的整体获利能力。

市场趋势

白细胞介素-31讯号路径抑制剂的商业性化应用，透过满足快速缓解症状的迫切需求，树立了新的治疗标准，使其区别于起效缓慢的频谱生物製药。与需要数週才能达到最佳疗效的传统2型发炎抑制剂不同，IL-31拮抗剂直接针对引起搔痒和睡眠障碍的神经通路，从而即时缓解症状。这正在影响着需要即时稳定生活品质的急性疼痛患者的处方行为。根据高德美公司2025年12月发布的新闻稿，一项3期临床试验的事后分析显示，接受nemolizumab治疗的患者中有17.2%在48小时内瘙痒强度显着降低，而安慰剂组仅为3.7%，这凸显了该机制在急性症状管理方面的商业性潜力。

此外，对抑癌素M受体β次单元抑制剂的研究代表着治疗方法的策略性转变，即同时针对神经发炎讯号路径和纤维化组织重塑。这些新型药物透过抑制抑癌素M受体β次单元，阻断IL-31和抑癌素M细胞激素，从而破坏导致搔痒和结节形成的双通路，而搔痒和结节正是难治性病例的特征。这种作用机转对于仅靠上游免疫调节不足以治疗的晚期纤维化病变患者尤其重要。根据Medscape于2025年12月报道，一项随机IIb期临床试验显示，接受高剂量bicsarelimab治疗的患者在第16週时，最严重搔痒数字评分量表（Worst Itch Numerical Rating Scale）评分平均降低了56.2%。此结果显着优于安慰剂组的14.5%的降低幅度，显示该药物在治疗这种难治性疾病方面具有更优的疗效。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球疣治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 副产品（皮质类固醇、抗组织胺药物、润肤剂、辣椒素乳膏等）
    • 按分销管道（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美寻常疣治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲寻常疣治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区寻常疣治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲寻常疣治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章 南美洲寻常疣治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球寻常疣治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Sanofi
  • Regeneron Pharmaceuticals
  • Galderma
  • Amgen
  • Incyte Corporation
  • Novartis
  • LEO Pharma
  • Trevi Therapeutics
  • Kiniksa Pharmaceuticals
  • VYNE Therapeutics

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17525

The Global Prurigo Nodularis Treatment Market is projected to expand from USD 975.66 Million in 2025 to USD 1169.07 Million by 2031, registering a compound annual growth rate (CAGR) of 3.06%. Treatment strategies for this chronic neuroimmune condition involve pharmacotherapeutic interventions such as topical corticosteroids, systemic neuromodulators, and targeted biologics, all aimed at mitigating debilitating pruritus and hyperkeratotic lesions. The market is primarily propelled by recent regulatory approvals of novel monoclonal antibodies that specifically target itch pathways, providing enhanced efficacy compared to traditional off-label agents, while a growing clinical emphasis on diagnosing underlying type 2 inflammatory comorbidities further enlarges the patient population eligible for systemic intervention.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 975.66 Million
Market Size 2031USD 1169.07 Million
CAGR 2026-20313.06%
Fastest Growing SegmentCorticosteroids
Largest MarketNorth America

However, the substantial acquisition costs associated with these advanced therapies pose a major challenge, potentially restricting market penetration in regions with limited healthcare funding or strict reimbursement policies. This financial burden is exacerbated by the need for long-term adherence to maintain therapeutic benefits and prevent symptom recurrence. For instance, the European Academy of Dermatology and Venereology reported in 2024 that clinical trial data indicated a 75% relapse rate among prior responders who discontinued nemolizumab treatment, underscoring the critical necessity for continuous disease management to sustain market value.

Market Driver

The commercialization of novel biologic therapies is fundamentally transforming the Global Prurigo Nodularis Treatment Market by introducing approved, targeted interventions that supersede less effective off-label options. Adoption rates are surging as newly authorized monoclonal antibodies demonstrate a superior ability to disrupt the itch-scratch cycle compared to traditional immunosuppressants, a shift supported by recent real-world evidence of therapeutic durability. As noted by Sanofi in September 2024 during the EADV Congress, an interim analysis of Dupilumab usage revealed that 50.0% of treated patients achieved a clinically meaningful reduction in itch intensity at six months; this high efficacy is essential for addressing the significant disease burden, which Galderma's August 2024 press release estimates affects up to 181,000 individuals in the United States alone, representing a vast addressable market for these commercialized biologics.

Simultaneously, robust clinical pipelines and R&D investments are accelerating market expansion, driven by a race to develop next-generation oral small molecules that combine high efficacy with convenient administration. Pharmaceutical companies are heavily investing in JAK inhibitors and other novel pathways to serve patients who may be refractory to injectable biologics or prefer oral dosing, with late-stage results showing promise for improved long-term control. According to Incyte's presentation at the September 2024 EADV Congress, 89% of patients who initially responded to a 45 mg dose of oral povorcitinib maintained their response through week 40, positive data that incentivizes continued funding and development to ensure a steady stream of innovative therapies capable of sustaining market value and competition over the coming decade.

Market Challenge

The high acquisition costs linked to novel pharmacotherapeutic interventions, particularly targeted biologics, constitute a significant barrier to the growth of the Global Prurigo Nodularis Treatment Market. Although these advanced therapies deliver improved clinical outcomes, their substantial pricing creates considerable hurdles for market penetration, especially in regions with stringent reimbursement frameworks or limited public healthcare funds. This financial pressure is compounded by the chronic nature of the disease, which requires long-term adherence to expensive regimens to prevent symptom recurrence, thereby straining payer budgets and increasing out-of-pocket expenses for patients.

As a result, payers often enforce restrictive access protocols that delay the uptake of premium treatments, negatively impacting market accessibility due to the substantial economic weight of the condition. According to data from the International Society for Pharmacoeconomics and Outcomes Research in 2024, real-world evidence revealed that patients with Prurigo Nodularis incurred significantly higher healthcare costs, with a difference of $5,736 per patient compared to matched controls. This elevated economic burden limits the widespread adoption of advanced therapies, subsequently hampering the overall revenue potential of the market.

Market Trends

The commercial adoption of Interleukin-31 signaling inhibitors is establishing a new standard of care by addressing the critical need for rapid symptom relief, distinguishing these therapies from slower-acting broad-spectrum biologics. Unlike traditional type 2 inflammation blockers that may take weeks to show optimal benefits, IL-31 antagonists directly target the neuronal pathways responsible for the immediate sensation of itch and sleep disruption, influencing prescribing behaviors for patients in acute distress who require immediate stabilization of their quality of life. According to a December 2025 press release from Galderma, post-hoc analysis of Phase III trials showed that 17.2% of patients treated with nemolizumab achieved a significant reduction in itch intensity within just 48 hours compared to only 3.7% in the placebo group, highlighting the commercial potential of this mechanism for acute symptom management.

Additionally, the investigation of Oncostatin M receptor beta blockers represents a strategic shift toward therapies that simultaneously target neuro-inflammatory signaling and fibrotic tissue remodeling. By inhibiting the beta subunit of the oncostatin M receptor, these novel agents block both IL-31 and oncostatin M cytokines, disrupting the dual pathways of pruritus and nodule formation that characterize refractory cases. This mechanism is particularly relevant for patients with highly fibrotic lesions who may not respond adequately to upstream immune modulation alone; as reported by Medscape in December 2025, a Phase 2b randomized trial demonstrated that high-dose vixarelimab resulted in a 56.2% decrease in mean Worst Itch-Numeric Rating Scale scores at week 16, significantly outperforming the 14.5% reduction in the placebo group and suggesting superior efficacy for difficult-to-treat phenotypes.

Key Market Players

  • Sanofi
  • Regeneron Pharmaceuticals
  • Galderma
  • Amgen
  • Incyte Corporation
  • Novartis
  • LEO Pharma
  • Trevi Therapeutics
  • Kiniksa Pharmaceuticals
  • VYNE Therapeutics

Report Scope

In this report, the Global Prurigo Nodularis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prurigo Nodularis Treatment Market, By Product

  • Corticosteroids
  • Anti-Histamines
  • Emollients
  • Capsaicin Cream
  • Others

Prurigo Nodularis Treatment Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Prurigo Nodularis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prurigo Nodularis Treatment Market.

Available Customizations:

Global Prurigo Nodularis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prurigo Nodularis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Corticosteroids, Anti-Histamines, Emollients, Capsaicin Cream, Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Prurigo Nodularis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Prurigo Nodularis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Prurigo Nodularis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Prurigo Nodularis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Distribution Channel

7. Europe Prurigo Nodularis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Prurigo Nodularis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Prurigo Nodularis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Prurigo Nodularis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Prurigo Nodularis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Prurigo Nodularis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Prurigo Nodularis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Prurigo Nodularis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Prurigo Nodularis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Prurigo Nodularis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Prurigo Nodularis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Prurigo Nodularis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Prurigo Nodularis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Prurigo Nodularis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Prurigo Nodularis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Prurigo Nodularis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Distribution Channel

10. South America Prurigo Nodularis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Prurigo Nodularis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Prurigo Nodularis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Prurigo Nodularis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Prurigo Nodularis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Sanofi
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Regeneron Pharmaceuticals
  • 15.3. Galderma
  • 15.4. Amgen
  • 15.5. Incyte Corporation
  • 15.6. Novartis
  • 15.7. LEO Pharma
  • 15.8. Trevi Therapeutics
  • 15.9. Kiniksa Pharmaceuticals
  • 15.10. VYNE Therapeutics

16. Strategic Recommendations

17. About Us & Disclaimer